J. Kevin Hicks

5.0k total citations · 1 hit paper
64 papers, 2.3k citations indexed

About

J. Kevin Hicks is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, J. Kevin Hicks has authored 64 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 20 papers in Molecular Biology and 17 papers in Pharmacology. Recurrent topics in J. Kevin Hicks's work include Pharmacogenetics and Drug Metabolism (17 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Genomics and Diagnostics (9 papers). J. Kevin Hicks is often cited by papers focused on Pharmacogenetics and Drug Metabolism (17 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Genomics and Diagnostics (9 papers). J. Kevin Hicks collaborates with scholars based in United States, United Kingdom and Canada. J. Kevin Hicks's co-authors include Andrea Gaedigk, Jesse J. Swen, Henry M. Dunnenberger, James M. Hoffman, Katrin Sangkuhl, Cyrine E. Haidar, Christine E. Canman, Julia Stingl, Todd C. Skaar and D Müller and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

J. Kevin Hicks

60 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants

2023 181 citations Katrin Sangkuhl, J. Kevin Hicks et al. Clinical Pharmacology & Therapeutics profile →

Peers

Countries citing papers authored by J. Kevin Hicks

Since Specialization

Citations

This map shows the geographic impact of J. Kevin Hicks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Kevin Hicks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Kevin Hicks more than expected).

Fields of papers citing papers by J. Kevin Hicks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Kevin Hicks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Kevin Hicks. The network helps show where J. Kevin Hicks may publish in the future.

Co-authorship network of co-authors of J. Kevin Hicks

This figure shows the co-authorship network connecting the top 25 collaborators of J. Kevin Hicks. A scholar is included among the top collaborators of J. Kevin Hicks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Kevin Hicks. J. Kevin Hicks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Germline POT1 Variants in a Pan-Cancer Cohort 2025 ·JCO Precision Oncology ·Pamela Brock, M. N. Webster, Sandya Liyanarachchi, Lindsey Byrne, Dale J. Hedges, Pat Gulhati, J. Kevin Hicks, Carlos H.F. Chan, Kenan Onel, (unknown), (unknown), (unknown), Juvianee Estrada‐Veras, Bodour Salhia, Lisen Axell, Laura L. Holman, Mohamed H. Abdel‐Rahman, Matthew D. Ringel	0
2	Impact of artificial intelligence on future clinical pharmacy research and scholarship 2025 ·JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY ·Alexandre Chan, William L. Baker, Daniel Abazia, Jerry L. Bauman, C. Lindsay DeVane, Kellie J. Goodlet, (unknown), J. Kevin Hicks, Ellen Jones, Chi‐Hua Lu, Donald C. Moore, Nicholas R. Nelson, (unknown), (unknown), Toby C. Trujillo, (unknown)	2
3	Unsupervised detection of rare events in liquid biopsy assays 2025 ·npj Precision Oncology ·(unknown), (unknown), (unknown), Stephanie N. Shishido, (unknown), Handong Xu, (unknown), (unknown), (unknown), (unknown), J. Kevin Hicks, Peter Kühn, Assad A. Oberai	1
4	Comparing the effectiveness of multimodal vs monomodal digital flashcards for L2 vocabulary learning 2025 ·Studies in English Language and Education ·J. Kevin Hicks, (unknown), (unknown)	0
5	Decoding pharmacogenomic test interpretation and application to patient care 2024 ·JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY ·(unknown), Larisa H. Cavallari, Jeannine S. McCune, Jennifer Trofe‐Clark, Christine M. Formea, (unknown), (unknown), (unknown), Shubha Bhat, (unknown), Qing Ma, (unknown), James M. Hoffman, J. Kevin Hicks, Kelly E. Caudle	0
6	Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care 2024 ·Journal of Molecular Diagnostics ·Aileen Y. Alontaga, Pedro Cano, (unknown), John Puskas, Paul A. Stewart, Eric A. Welsh, (unknown), J. Kevin Hicks, Andreas Saltos, Aaron Bossler, Eric B. Haura, John M. Koomen, Theresa A. Boyle	2
7	CHEK2 Founder Variants and Thyroid Cancer Risk 2024 ·Thyroid ·Pamela Brock, (unknown), Taina T. Nieminen, Carlos H.F. Chan, Wendy Kohlmann, (unknown), Song Yao, (unknown), (unknown), Jill Kolesar, Bodour Salhia, Pat Gulhati, J. Kevin Hicks, Matthew D. Ringel	4
8	Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy 2023 ·Clinical Pharmacology & Therapeutics ·Daniel L. Hertz, D. Max Smith, Stuart A. Scott, Jai N. Patel, J. Kevin Hicks	22
9	Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data 2023 ·Cancers ·Julian A. Marin‐Acevedo, Bruna Pellini, (unknown), J. Kevin Hicks, Alberto Chiappori	23
10	Clinical outcomes with frontline immunotherapy (IO) in BRAF-mutant NSCLC. 2023 ·Journal of Clinical Oncology ·Julian A. Marin‐Acevedo, Ram Thapa, Sonam Puri, J. Kevin Hicks, Jhanelle E. Gray	1
11	Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice 2021 ·JCO Precision Oncology ·J. Kevin Hicks, Rachel Howard, (unknown), Jacob J. Adashek, Karen K. Fields, Jhanelle E. Gray, Bryan McIver, (unknown), (unknown), Randa Perkins, Edmondo Robinson, Ankita Tandon, Jamie K. Teer, Joseph Markowitz, Dana E. Rollison	31
12	<p>Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network</p> 2020 ·Pharmacogenomics and Personalized Medicine ·Benjamin Q. Duong, Meghan J. Arwood, J. Kevin Hicks, Amber L. Beitelshees, Francesco Franchi, (unknown), Nita A. Limdi, (unknown), Aniwaa Owusu Obeng, Natasha Petry, Sony Tuteja, Amanda R. Elsey, Larisa H. Cavallari, Kristin Wiisanen	11
13	Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice 2019 ·JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY ·J. Kevin Hicks, Christina L. Aquilante, Henry M. Dunnenberger, Roseann S. Gammal, Ryan S. Funk, Samuel L Aitken, David R. Bright, James C. Coons, (unknown), (unknown), (unknown), James C. Lee	54
14	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC 2018 ·PLoS ONE ·Michael E. Goldberg, Meagan Montesion, Lauren Young, James Suh, Joel Greenbowe, Mark Kennedy, Giuseppe Giaccone, Wallace Akerley, Afshin Dowlati, Ben Creelan, J. Kevin Hicks, Paul J. Hesketh, Karen Kelly, Jonathan W. Riess, Vincent A. Miller, Philip J. Stephens, Garrett M. Frampton, Siraj M. Ali, Jeffrey P. Gregg, Lee A. Albacker	15
15	Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update 2017 ·Data Archiving and Networked Services (DANS) ·J. Kevin Hicks, Katrin Sangkuhl, Jesse J. Swen, Vicki L. Ellingrod, Daniel J. Müller, Kazutaka Shimoda, Jeffrey R. Bishop, Evan D. Kharasch, Todd C. Skaar, Andrea Gaedigk, Henry M. Dunnenberger, Teri E. Klein, Kelly E. Caudle, Julia Stingl	57
16	ATDC/TRIM29 Phosphorylation by ATM/MAPKAP Kinase 2 Mediates Radioresistance in Pancreatic Cancer Cells 2014 ·Cancer Research ·Lidong Wang, Huibin Yang, Phillip L. Palmbos, Gina M. Ney, (unknown), Dawn M. Coleman, (unknown), Mary A. Davis, Min Zhang, Wenhua Tang, J. Kevin Hicks, (unknown), Jayendra Prasad, Theodore S. Lawrence, Liang Xu, Xiaochun Yu, Christine E. Canman, Mats Ljungman, Diane M. Simeone	51
17	Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization 2014 ·Current Drug Metabolism ·J. Kevin Hicks, Jesse J. Swen, Andrea Gaedigk	126
18	Comparison of European Medicines Agency (EMA) and Food and Drug Administration (FDA) procedures for evaluating scientific and regulatory issues of clinical studies during the development of medicinal products: Experience of a global imaging clinical research organization 2013 ·(unknown), J. Kevin Hicks	3
19	REV1 and polymerase ζ facilitate homologous recombination repair 2011 ·Nucleic Acids Research ·Shilpy Sharma, J. Kevin Hicks, (unknown), (unknown), Joon Young Ahn, Thomas W. Glover, Christine E. Canman	102
20	Durable "Green" Concrete from Activated Pozzolan Cement 2010 ·J. Kevin Hicks	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact